Eligibility Criteria for Biologic Disease-Modifying Antirheumatic Drugs in Axial Spondyloarthritis: Going Beyond BASDAI

RMD Open - United Kingdom
doi 10.1136/rmdopen-2019-001145
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Switching Biological Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis: Results From a Systematic Literature Review

RMD Open
RheumatologyAllergyImmunology
2017English

Hypersensitivity Reactions to Biologic Disease Modifying Antirheumatic Drugs: Experience From the TTSH Singapore Biologics Registry

Clinical and Translational Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2014English

Assessing the Effectiveness of Synthetic and Biologic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis &Ndash; A Systematic Review

Psoriasis: Targets and Therapy
DermatologyRheumatology
2015English

Predictors of Stopping and Starting Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis

Arthritis Care and Research
Rheumatology
2014English

Lipid Profiles in Rheumatoid Arthritis Patients Treated With Disease-Modifying Antirheumatic Drugs

Reumatologia
RheumatologyAllergyImmunology
2014English

Safety of Abatacept Compared With Other Biologic and Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Data From an Observational Study

Arthritis Research & Therapy
2019English

Real-World Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany

Clinical Therapeutics
Pharmacology
2017English

Persistence With Biological Disease-Modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Drugs - Real World Outcomes
Pharmacology
2018English

Changes in Use of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States During 1983-2009

Arthritis Care and Research
Rheumatology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy